 Efficacy safety considerations women uterine leiomyomas gonadotropin-releasing hormone agonists estrogen threshold hypothesis hormone agonists reversible hypogonadotropic hypogonadal environment common estrogen-sensitive benign neoplasms size gonadotropin-releasing hormone agonist treatment gonadotropin-releasing hormone agonist therapy women amenorrheic discontinuation gonadotropin-releasing hormone agonist treatment uterine myoma size increase return menstrual patterns Concerns safety long-term hypoestrogenism long-term gonadotropin-releasing hormone agonist administration undesirable treatment strategy article use gonadotropin-releasing hormone agonists preoperative therapy women hysterectomy myomectomy combination gonadotropin-releasing hormone agonist estrogen-progestin add-back treatment potential long-term medical therapy women symptomatic leiomyomas estrogen threshold hypothesis effects estrogen concentrations different tissues